ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.702,63
0,33%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) News

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KYMR
DatumZeitQuelleÜberschriftSymbolFirma
01/06/202414h00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
29/05/202413h00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
23/05/202423h00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
22/05/202417h20GlobeNewswire Inc.Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
14/05/202416h00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
02/05/202413h00GlobeNewswire Inc.Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
25/04/202413h00GlobeNewswire Inc.Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2NASDAQ:KYMRKymera Therapeutics Inc
08/04/202413h00GlobeNewswire Inc.Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
08/03/202416h00GlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
05/03/202400h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
05/03/202400h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
05/03/202400h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
04/03/202423h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
04/03/202423h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
28/02/202413h00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
27/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
22/02/202413h32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KYMRKymera Therapeutics Inc
22/02/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
22/02/202413h00GlobeNewswire Inc.Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
15/02/202413h00GlobeNewswire Inc.Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22NASDAQ:KYMRKymera Therapeutics Inc
10/02/202401h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
09/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
31/01/202413h00GlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare ConferenceNASDAQ:KYMRKymera Therapeutics Inc
09/01/202415h17GlobeNewswire Inc.Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
09/01/202415h15GlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
05/01/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
05/01/202422h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
05/01/202412h00GlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $275 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
04/01/202422h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR

Kürzlich von Ihnen besucht

TSXV
THNK
Think Research
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten